Editorial: Comprehensive insights into mitral valve prolapse: from biology to future perspectives of treatment passing through diagnostic tools, surgical techniques, and transcatheter options.

Tables number: 0Funding statement: no funding Disclosures: none TEXT Mitral valve prolapse (MVP) affects 2% to 3% of the population and it represents first cause of 2 primary chronic mitral regurgitation (MR) (1). Although as "an abnormal systolic protrusion mitral valve in the left atrium", MVP includes a wide spectrum of anatomical conditions, 4 ranging from Barlow's disease to fibroelastic deficiency (FED). Barlow's disease patients are younger, 5 present redundant myxoid leaflets and elongated (rarely ruptured) chordae, whereas FED is associated 6 with translucent tissue, chordal rupture and flail leaflet in older patients(2). 7Despite thousands of articles on MVP, such pathological entity still presents some blind spots: a full 8 comprehension of its underlying biological bases is far from achievement(3), as well as the rising 9 evidence of a link between MVP, mitral annular disjunction (MAD) and malignant arrhythmias(4). 10Given the excellent results of surgical repair(5), indications to treatment are in continuous evolution 11 aiming at weighing the predicted risk, repair feasibility and precocious markers of cardiac 12 impairment(6). This trend translates into a parallel effort to combine all diagnostic tools for detecting 13 as early as possible criteria of MR severity and their possible impact on heart function.